Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H17N3O8 |
Molecular Weight | 319.268 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12O[C@@]3(O)O[C@]([H])([C@]4([H])[C@@H](O)N=C(N)N[C@]4([C@@H]1O)[C@@H]3O)[C@@]2(O)CO
InChI
InChIKey=CFMYXEVWODSLAX-QOZOJKKESA-N
InChI=1S/C11H17N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-20H,1H2,(H3,12,13,14)/t2-,3-,4-,5+,6-,7+,9+,10-,11+/m1/s1
Molecular Formula | C11H17N3O8 |
Molecular Weight | 319.268 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tetrodotoxin (TTX) is a potent marine neurotoxin that blocks voltage-gated sodium channels (VGSCs). VGSCs play a critical role in neuronal function under both physiological and pathological conditions. TTX has been extensively used to functionally characterize VGSCs, which can be classified as TTX-sensitive or TTX-resistant channels according to their sensitivity to this toxin. Wex Pharmaceuticals is investigating tetrodotoxin for the treatment of chronic and breakthrough pain. The toxin is currently undergoing Phase III clinical trials in Canada as a systemic analgesic for inadequately controlled pain due to advanced cancer, especially where the pain has neuropathic features. In addition, TTX is in Phase II clinical trials to study its ability in moderate to severe neuropathic pain caused by chemotherapy.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22363247/
Curator's Comment: cross the blood brain barrier very poorly
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24607901 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22412801 |
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.9914 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32784930 |
45 μL single, subcutaneous dose: 45 μL route of administration: Subcutaneous experiment type: SINGLE co-administered: |
TETRODOTOXIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.4983 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32784930 |
45 μL single, subcutaneous dose: 45 μL route of administration: Subcutaneous experiment type: SINGLE co-administered: |
TETRODOTOXIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.28 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32784930 |
45 μL single, subcutaneous dose: 45 μL route of administration: Subcutaneous experiment type: SINGLE co-administered: |
TETRODOTOXIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Tetrodotoxin for moderate to severe cancer pain: a randomized, double blind, parallel design multicenter study. | 2008 Apr |
|
On the origins and biosynthesis of tetrodotoxin. | 2011 Jul |
|
A multicentre open-label safety and efficacy study of tetrodotoxin for cancer pain. | 2011 Jun |
|
The molecular mystique of tetrodotoxin. | 2013 Mar 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00725114
subcutaneous 30 µg twice daily for 4 days
intramuscular injection (1 ml volume), twice a day for four consecutive days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28192153
There was used micro-electrode array (MEA) recordings as an integrated measure of neurotransmission to demonstrate that tetrodotoxin inhibited neuronal electrical activity in both primary rat cortical cultures and human-induced pluripotent stem cell (hIPSC)-derived iCell® neurons in co-culture with hIPSC-derived iCell® astrocytes, with IC50 values of 7 and 10nM, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:39:49 GMT 2023
by
admin
on
Fri Dec 15 15:39:49 GMT 2023
|
Record UNII |
3KUM2721U9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C93038
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
||
|
NCI_THESAURUS |
C688
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11174599
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
4368-28-9
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
3KUM2721U9
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
DB05232
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
300000037002
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
TETRODOTOXIN
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
10243
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
D013779
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
9506
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
C78845
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
3543
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
m10664
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
224-458-8
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY | |||
|
DTXSID10881342
Created by
admin on Fri Dec 15 15:39:49 GMT 2023 , Edited by admin on Fri Dec 15 15:39:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|